Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 5/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.38 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448531 | 1.00 | SLCO1B1 (0.44) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL29448518 | 0.92 | SLCO1B1 (0.45) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL23697665 | 0.92 | SLCO1B1 (0.45) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL29448508 | 0.91 | SLCO1B1 (0.44) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL23697624 | 0.91 | SLCO1B1 (0.44) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL23671225 | 0.88 | SLCO1B1 (0.55) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL29448507 | 0.87 | SLCO1B1 (0.41) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL23697693 | 0.87 | SLCO1B1 (0.41) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL23697214 | 0.84 | SLCO1B1 (0.44) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL29448505 | 0.84 | SLCO1B1 (0.44) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112055711-B | Cyclohexylic acid triazolazine as LPA antagonist | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-29 | — | — | US | disclosed |
| CN-112055711-A | Cyclohexyl acid triazole azines as LPA antagonists | 百时美施贵宝公司 | 2020-12-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1638/4885ABCB11 1865/4885ABCC3 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.